PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows
Wells Fargo highlighted the agreement’s $1.9 billion milestone potential, 40% U.S. profit-sharing terms, and double-digit royalties on ex-U.S. sales.
3 Top Stocks That Could Still Rocket Higher in 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof.
Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024
Stocks that traded heavily or had substantial price changes on Friday: Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
Bad news for one player does not always equal good news for another.
Why PTC Therapeutics Soared 15% Higher Today
The company scored a $1 billion upfront payment for expanding a commercial partnership.